Idetrexed (trisodium)
Idetrexed (ONX 0801) trisodium is a thymidylate synthase (TS) inhibitor with a Ki of 1.2 nM. Idetrexed trisodium can be specifically transported into α-folate receptor (α-FR) -overexpressing tumors, such as ovarian cancer[1][2].
Product Specifications
CAS Number
1097638-00-0
Product Name Alternative
BGC 945 (trisodium) ; ONX 0801 (trisodium) ; CB 300945 (trisodium)
UNSPSC
12352005
Target
Thymidylate Synthase
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/onx-0801-trisodium.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@H](C(O[Na])=O)CCC(N[C@@H](C(O[Na])=O)CCC(O[Na])=O)=O)C1=CC=C(N([C@H]2CCC3=C2C=C4C(NC(CO)=NC4=O)=C3)CC#C)C=C1
Molecular Formula
C32H30N5Na3O10
Molecular Weight
713.58
References & Citations
[1]Anna Tochowicz, et al. Development and binding mode assessment of N-[4-[2-propyn-1-yl[ (6S) -4,6,7,8-tetrahydro-2- (hydroxymethyl) -4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem. 2013 Jul 11;56 (13) :5446-55.|[2]David D Gibbs, et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005 Dec 15;65 (24) :11721-8.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog